Novo Nordisk Slashes US List Prices Of Several Insulin Products By Up To 75%

RTTNews | 850 days ago
Stocktwits
Novo Nordisk Slashes US List Prices Of Several Insulin Products By Up To 75%

(RTTNews) - Healthcare company Novo Nordisk Inc. (NVO) announced Tuesday it is lowering the U.S. list prices of several pre-filled insulin pens and vials by up to 75% for people living with type 1 and type 2 diabetes.

The products include both pre-filled pens and vials of basal (long-acting), bolus (short-acting) and pre-mix insulins, specifically Levemir, Novolin, NovoLog and NovoLog Mix 70/30.

Novo Nordisk is also reducing the list price of unbranded biologics to match the lowered price of each respective branded insulin. These changes will go into effect on January 1, 2024.

Novo Nordisk currently provides co-pay support for a number of insulin products, meaning eligible patients can pay $25 to $35 for their insulin.

Novo Nordisk recognizes that some patients find it difficult to pay for healthcare, including insulin. As such, the Company remains committed to reducing the burden of out-of-pocket costs, helping transform the complex pricing system, and fostering better pricing predictability.

Novo Nordisk continually reviews and revises its offerings as well as works with diverse stakeholders to create solutions for differing patient needs.

Tags: NVO
Stocktwits
read more
Novo Nordisk Stock Climbs On Higher Q1 Results; Cuts FY25 Outlook

Novo Nordisk Stock Climbs On Higher Q1 Results; Cuts FY25 Outlook

Shares of Novo Nordisk A/S were gaining around 6 percent in Denmark as well as around 7 percent in the pre-market activity on the NYSE, after the Danish drug major reported Wednesday higher profit and sales in its first quarter, mainly reflecting improved results of its blockbuster weight loss drug Wegovy. Meanwhile, the company trimmed fiscal 2025 outlook for sales and operating profit growth...
RTTNews | 65 days ago
Novo Nordisk Plans $4.1 Bln NC Facility To Boost Obesity Drug Supply

Novo Nordisk Plans $4.1 Bln NC Facility To Boost Obesity Drug Supply

Danish drug maker Novo Nordisk announced its plans to invest $4.1 billion or about 27 billion Danish kroner to build a new manufacturing plant in Clayton, North Carolina with a view to expanding its manufacturing capacity in the United States. In the new plant, the company plans to produce current and future injectable treatments for people with obesity and other serious chronic diseases.
RTTNews | 381 days ago
Bay Street Likely To Open Lower

Bay Street Likely To Open Lower

Canadian shares look headed for a weak start on Friday due to trade war concerns, although fairly firm crude oil and bullion prices may help limit the market's downside. Data showing an increase in Canadian employment in the month of June and a drop in the unemployment rate may also aid sentiment a bit.
RTTNews | 2h 5min ago
Pound Falls As U.K. Economy Contracts For Second Straight Month

Pound Falls As U.K. Economy Contracts For Second Straight Month

The British pound weakened against other major currencies in the European session on Friday, as the UK economy shrank for the second consecutive month in May, adding challenges to Chancellor Rachel Reeves in achieving her self-imposed borrowing rules.
RTTNews | 2h 13min ago
Pound Falls Against Majors

Pound Falls Against Majors

The British pound weakened against other major currencies in the European session on Friday.
RTTNews | 2h 35min ago
Tools
Economic Calendar
Market Hours
Interest Rates
Holidays Calendar
Forex Market
Forex Volatility
Forex Correlation
Forex News
forex analysis
COT Data
Liquidity
Forex Calculators
Forex Heat Map
Indicators Heatmap
Community
Community
Systems
Most Popular Systems
Strategies
Contests
Forex Charts
Forex Sentiment
Sentiment Indicator
Reviews
Brokers
Prop Trading Firms
VPS Services
Signal Providers
EA Programming Services
Affiliate Programs
PAMM Broker Services
Rebate Program Services
Trading Platforms
Expert Advisors
Crypto Exchanges
Trading Courses
Brokers
Forex Spreads
Forex Broker Quotes
Forex Broker Swaps
Forex Broker Volume
Forex Broker Promotions Press Release
Platform
Widgets
Features
API
RSS
Stock Portfolio
Affiliate Software
Advanced Charts
Support
FAQ
Help
Contact Us
Report a Bug!
About
Blog
© 2025 Myfxbook Ltd. All Rights Reserved.
HIGH RISK WARNING: Foreign exchange trading carries a high level of risk that may not be suitable for all investors. Leverage creates additional risk and loss exposure. Before you decide to trade foreign exchange, carefully consider your investment objectives, experience level, and risk tolerance. You could lose some or all of your initial investment. Do not invest money that you cannot afford to lose. Educate yourself on the risks associated with foreign exchange trading, and seek advice from an independent financial or tax advisor if you have any questions. Any data and information is provided 'as is' solely for informational purposes, and is not intended for trading purposes or advice. Past performance is not indicative of future results.